DE60129432D1 - Verfahren zur rückfaltung von proteinen mit freien cysteinresten - Google Patents

Verfahren zur rückfaltung von proteinen mit freien cysteinresten

Info

Publication number
DE60129432D1
DE60129432D1 DE60129432T DE60129432T DE60129432D1 DE 60129432 D1 DE60129432 D1 DE 60129432D1 DE 60129432 T DE60129432 T DE 60129432T DE 60129432 T DE60129432 T DE 60129432T DE 60129432 D1 DE60129432 D1 DE 60129432D1
Authority
DE
Germany
Prior art keywords
proteins
recycling
rest
novel methods
free cystein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129432T
Other languages
English (en)
Other versions
DE60129432T2 (de
Inventor
Mary S Rosendahl
George N Cox
Daniel H Doherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bolder Biotechnology Inc
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Application granted granted Critical
Publication of DE60129432D1 publication Critical patent/DE60129432D1/de
Publication of DE60129432T2 publication Critical patent/DE60129432T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60129432T 2000-05-16 2001-05-16 Verfahren zur rückfaltung von proteinen mit freien cysteinresten Expired - Lifetime DE60129432T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20461700P 2000-05-16 2000-05-16
US204617P 2000-05-16
PCT/US2001/016088 WO2001087925A2 (en) 2000-05-16 2001-05-16 Methods for refolding proteins containing free cysteine residues

Publications (2)

Publication Number Publication Date
DE60129432D1 true DE60129432D1 (de) 2007-08-30
DE60129432T2 DE60129432T2 (de) 2008-04-17

Family

ID=22758675

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129432T Expired - Lifetime DE60129432T2 (de) 2000-05-16 2001-05-16 Verfahren zur rückfaltung von proteinen mit freien cysteinresten

Country Status (13)

Country Link
US (3) US7306931B2 (de)
EP (1) EP1284987B1 (de)
JP (2) JP4873818B2 (de)
CN (1) CN1318443C (de)
AT (1) ATE367398T1 (de)
AU (2) AU2001274853B2 (de)
CA (1) CA2408851C (de)
DE (1) DE60129432T2 (de)
ES (1) ES2290142T3 (de)
HK (1) HK1050014A1 (de)
IL (2) IL152804A0 (de)
NZ (1) NZ522847A (de)
WO (1) WO2001087925A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
NZ502375A (en) * 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US20080076706A1 (en) * 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6677433B2 (en) * 1999-01-27 2004-01-13 The Regents Of The University Of California Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1314739A1 (de) 2001-11-22 2003-05-28 Bayer Ag Verfahren zur Renaturierung rekombinanter, Disulfid-enthaltender Proteine bei hohen Proteinkonzentrationen in Gegenwart von Aminen
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003078461A1 (en) 2002-03-20 2003-09-25 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
PL219741B1 (pl) 2002-12-26 2015-07-31 Mountain View Pharmaceuticals Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie
CA2509260C (en) 2002-12-31 2012-10-02 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
SI1596887T1 (sl) 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004227937B2 (en) 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1675871A2 (de) 2003-10-10 2006-07-05 Xencor Inc. Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
JP2008500275A (ja) * 2003-12-31 2008-01-10 セントカー・インコーポレーテツド Ｎ末端の遊離チオールを有する新規な組み換えタンパク質
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
CN101115769A (zh) 2004-05-19 2008-01-30 马克西根公司 干扰素-α多肽和偶联物
US8518403B2 (en) * 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
ES2355642T3 (es) * 2004-07-16 2011-03-29 Nektar Therapeutics Conjugados que comprenden una porcion de gm-csf y un polimero.
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
DE102004041639A1 (de) * 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
ES2572779T3 (es) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US7678578B2 (en) * 2005-02-07 2010-03-16 Beckman Coulter, Inc. Cell permeabilization and stabilization reagent and method of use
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
JP2008545393A (ja) 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
CN101045742B (zh) * 2006-03-27 2011-12-21 华北制药集团新药研究开发有限责任公司 重组人粒细胞集落刺激因子的复性纯化工艺
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2213733A3 (de) * 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Analoge des Faktor IX mit verlängerter Halbwertszeit in vivo
AU2007272412B2 (en) 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
JP5608368B2 (ja) * 2006-08-01 2014-10-15 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
AU2012203658B2 (en) * 2007-01-10 2014-05-08 Protgen Ltd. Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US8329655B2 (en) 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CN104689333B (zh) 2007-08-27 2018-05-29 拉蒂奥法姆有限责任公司 G-csf 缀合物的液体制剂
WO2009058203A1 (en) * 2007-10-29 2009-05-07 Albert Einstein College Of Medicine Of Yeshiva University Radiolabeled monoclonal antibodies, methods of preparation using tcep, and uses thereof
WO2009086656A1 (zh) * 2007-12-29 2009-07-16 Biosteed Gene Expression Tech. Co., Ltd. Y型聚乙二醇修饰的g-csf及其制备方法和应用
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2268672A1 (de) * 2008-03-12 2011-01-05 Imclone LLC Anti-tyrp1-antikörper
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
KR101546563B1 (ko) 2008-12-09 2015-08-28 할로자임, 아이엔씨 연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
EP3660032A1 (de) 2009-06-25 2020-06-03 Amgen, Inc Erfassungs-/reinigungsverfahren für in einem nichtsäugersystem exprimierte proteine
IN2012DN03219A (de) 2009-09-17 2015-10-23 Baxter Healthcare Sa
AU2011208620B2 (en) * 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
BR112012018116B1 (pt) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Conjugados de hormônio do crescimento com eficácia in vivo prolongada
CA2789615A1 (en) * 2010-03-17 2011-09-22 Biogenerix Gmbh Method for obtaining biologically active recombinant human g-csf
EP2595624B1 (de) 2010-07-20 2018-01-31 Halozyme, Inc. Verfahren zur linderung bzw. vermeidung der nebenwirkungen im zusammenhang mit der verabreichung eines anti-hyaluronan-mittels
WO2012064867A1 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics Pharmacologically active polymer-g-csf conjugates
WO2012106463A2 (en) * 2011-02-01 2012-08-09 Fate Therapeutics, Inc. Cardiotrophin related molecules for enhanced therapeutics
EP2672958A1 (de) 2011-02-08 2013-12-18 Halozyme, Inc. Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
AU2012250614B2 (en) 2011-05-05 2016-02-11 Pharma Cinq, Llc Complement factor B analogs and their uses
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
EP2720713A2 (de) 2011-06-17 2014-04-23 Halozyme, Inc. Kontinuierliches subkutanes insulininfusionsverfahren mit einem hyaluronanabbauenden enzym
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
SG11201401797TA (en) 2011-10-24 2014-09-26 Halozyme Inc Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
EP2890394B1 (de) 2012-08-31 2019-05-01 GlaxoSmithKline Biologicals SA Stabilisierte proteine zur immunisierung gegen staphylococcus aureus
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US10065996B2 (en) * 2012-11-16 2018-09-04 Iba Gmbh Streptavidin muteins and methods of using them
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015086853A1 (en) * 2013-12-13 2015-06-18 Novo Nordisk Health Care Ag Method for thioether conjugation of proteins
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
WO2021216801A1 (en) * 2020-04-22 2021-10-28 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
MX9203641A (es) 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4677196A (en) 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
DE3537708A1 (de) 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
JPH01132598A (ja) * 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
DE68929273T2 (de) 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5223407A (en) 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0458064B1 (de) 1990-05-04 1998-02-25 American Cyanamid Company Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
CN1039330C (zh) * 1992-07-02 1998-07-29 皮特曼-穆尔有限公司 一种从含有无活性蛋白的溶液中回收生物活性形式重组蛋白的方法
AU6048294A (en) 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JPH10500693A (ja) * 1994-05-24 1998-01-20 アムジエン・ブルダー・インコーポレーテツド 改変型インスリン様増殖因子
WO2000015796A2 (en) * 1998-09-16 2000-03-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE19535853C2 (de) 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
JPH10234386A (ja) * 1996-12-26 1998-09-08 Takeda Chem Ind Ltd 成長ホルモン類の製造方法
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
EP1047771B1 (de) 1998-01-12 2003-04-23 G.D. Searle & Co. Verfahren zur angiostatinrückfaltung
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
CN1210400C (zh) 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
WO2001054981A2 (en) 2000-01-12 2001-08-02 Allison Advanced Development Company Propulsion module
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
US6692264B2 (en) 2001-11-13 2004-02-17 General Motors Corporation Elastomeric connector for fuel cell stack cell voltage monitor
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same

Also Published As

Publication number Publication date
CN1318443C (zh) 2007-05-30
US20040018586A1 (en) 2004-01-29
CA2408851A1 (en) 2001-11-22
EP1284987B1 (de) 2007-07-18
EP1284987A2 (de) 2003-02-26
JP5517991B2 (ja) 2014-06-11
IL152804A0 (en) 2003-06-24
JP4873818B2 (ja) 2012-02-08
AU7485301A (en) 2001-11-26
CN1443194A (zh) 2003-09-17
HK1050014A1 (en) 2003-06-06
NZ522847A (en) 2004-11-26
US20110189124A1 (en) 2011-08-04
US8932828B2 (en) 2015-01-13
DE60129432T2 (de) 2008-04-17
JP2011173911A (ja) 2011-09-08
IL152804A (en) 2010-11-30
AU2001274853C1 (en) 2001-11-26
WO2001087925A3 (en) 2002-08-01
WO2001087925A2 (en) 2001-11-22
ATE367398T1 (de) 2007-08-15
US7306931B2 (en) 2007-12-11
US20090269804A1 (en) 2009-10-29
ES2290142T3 (es) 2008-02-16
CA2408851C (en) 2011-07-12
AU2001274853B2 (en) 2007-03-22
JP2004508014A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60129432D1 (de) Verfahren zur rückfaltung von proteinen mit freien cysteinresten
BR122013003013B8 (pt) proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
Lepage et al. Purification and characterization of the sea urchin embryo hatching enzyme
ATE499382T1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE59509642D1 (de) Verfahren zur modifizierung der stabilität von antikörpern
ATE244729T1 (de) Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease
RS50426B (sr) Tenascin -c ligandi nukleinske kiseline
DE60335726D1 (de) Chromoprotein und fluoroproteine
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
ATE323763T1 (de) Dna & protein bindende miniatur proteine
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
DE60224576D1 (de) Neues peptid sy
DE60234811D1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
DE3687995T2 (de) Verfahren zur reinigung von interferon und so hergestellte zusammensetzung.
NO20020573D0 (no) Sekvens
KR880001698A (ko) 단백질 합성의 억제제, 그의 분리방법, 그의 용도 및 그를 함유하는 약학 조성물
DE60027581D1 (de) Design von immunogene
PT86944A (pt) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
DE60117754D1 (de) Verfahren zur herstellung von rekombinantem trypsin
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
DE3880758D1 (de) Von monozyten abstammendes gefaesswirksames protein und dessen analogen, verfahren zu seiner gewinnung und ihre verwendungen fuer therapeutische zwecke und zur antikoerperherstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition